EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer

Siraje Mahmud iD, Lisa Dwyer Orr iD, Mika Cline iD, Ayda Mirsalehi iD, Monica Lisi iD, Laura Ensley iD, Lorraine Brisbin iD, R Steven Paulson iD

The Oncologist · 08.07.2026 · 31 (8)

DOI: 10.1093/oncolo/oyag243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 27.06.2026. Verfasst von Siraje Mahmud und 7 weiteren Autor:innen. Beteiligte Einrichtung: Precision Health Informatics, LLC, Dallas, TX 75251, United States. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Urinary Bladder Neoplasms, Biomarkers, Tumor, Prostatic Neoplasms. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

National clinical guidelines recommend biomarker testing to identify actionable alterations across cancers, supporting personalized treatment.

Methods

This retrospective database study characterized biomarker testing patterns among adult patients newly diagnosed with metastatic non-small cell lung cancer (NSCLC), prostate cancer, or bladder cancer (January 2018–December 2022), receiving care within a large regional community oncology network in the West South-Central United States.

Results

Of 18 491 patients with NSCLC, 20 810 with prostate cancer, and 4120 with bladder cancer, 7383 (40%), 4985 (24%), and 888 (22%), respectively, had metastatic disease. For these metastatic subgroups, biomarker testing rates were 80% (NSCLC), 34% (prostate), and 42% (bladder). Median time from disease diagnosis to first test order was 10 days (NSCLC), 98 days (prostate), and 23 days (bladder), with differences observed across racial and ethnic groups. Among tested patients, actionable mutations were identified in 29% (NSCLC), 25% (prostate), and 14% (bladder) of patients, and targeted therapy was received by 54%, 15%, and 38% of these patients, respectively. Among patients who initiated treatment prior to receipt of test results, 72% (NSCLC), 12% (prostate), and 30% (bladder) subsequently switched to targeted therapy following a positive result. Testing rates increased between 2018 and 2022 for all cohorts; result turnaround times improved in prostate and bladder cancers.

Conclusions

Biomarker testing was highest in metastatic NSCLC and lower in prostate and bladder cancer in this community oncology setting. Despite improvements over time, gaps remain in timely testing and use of targeted therapies, highlighting opportunities to optimize precision oncology implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungUrinary Bladder NeoplasmsBiomarkers, TumorProstatic NeoplasmsLung NeoplasmsHumansMaleAgedRetrospective StudiesMiddle AgedFemale

Stichwörter der Autor:innen

biomarkerbladder cancermolecular analysisnon-small cell lung cancerprostate cancer

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Precision Health Informatics, LLC, Dallas, TX 75251, United States.
  • Johnson & Johnson, Titusville, NJ 08560, United States.
  • Texas Oncology, Dallas, TX 75251, United States.

ORCID-Profile: Siraje Mahmud, Lisa Dwyer Orr, Mika Cline, Ayda Mirsalehi, Monica Lisi, Laura Ensley, Lorraine Brisbin, R Steven Paulson

Förderung

  • Johnson & Johnson

Zitieren

APA

Mahmud, S., Dwyer Orr, L., Cline, M., Mirsalehi, A., Lisi, M., Ensley, L., Brisbin, L., & Paulson, R. S. (2026). Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer. The Oncologist, 31(8). https://doi.org/10.1093/oncolo/oyag243

Vancouver

Mahmud S, Dwyer Orr L, Cline M, Mirsalehi A, Lisi M, Ensley L, et al. Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer. The Oncologist. 2026;31(8). doi:10.1093/oncolo/oyag243

BibTeX
@article{Mahmud2026,
  author = {Mahmud, Siraje and Dwyer Orr, Lisa and Cline, Mika and Mirsalehi, Ayda and Lisi, Monica and Ensley, Laura and Brisbin, Lorraine and Paulson, R Steven},
  title = {Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {8},
  doi = {10.1093/oncolo/oyag243}
}
Kostenlos starten →